AR011178A1 - Compuesto de sal de sodio de (acido (e) 4,6-dicloro-3-(2-oxo-1- fenilpirrolidin-3-ilideno-metil)-1h-indol-2-carboxilico en su forma hidratada,proceso para su preparacion, composicion farmaceutica que lo contiene y metodo de tratamiento utilizando dicho compuesto - Google Patents
Compuesto de sal de sodio de (acido (e) 4,6-dicloro-3-(2-oxo-1- fenilpirrolidin-3-ilideno-metil)-1h-indol-2-carboxilico en su forma hidratada,proceso para su preparacion, composicion farmaceutica que lo contiene y metodo de tratamiento utilizando dicho compuestoInfo
- Publication number
- AR011178A1 AR011178A1 ARP980100948A ARP980100948A AR011178A1 AR 011178 A1 AR011178 A1 AR 011178A1 AR P980100948 A ARP980100948 A AR P980100948A AR P980100948 A ARP980100948 A AR P980100948A AR 011178 A1 AR011178 A1 AR 011178A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- preparation
- treatment
- sodium salt
- ilideno
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
Una forma hidratada cristalina de la sal de sodio del compuesto de formula (I), los procesos para su preparacion y su uso en terapia. Dichoscompuestos son utiles para el tratamiento o prevencion de danos neurotoxicos y enfermedades degenerativas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9704498.6A GB9704498D0 (en) | 1997-03-05 | 1997-03-05 | Chemical compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR011178A1 true AR011178A1 (es) | 2000-08-02 |
Family
ID=10808697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980100948A AR011178A1 (es) | 1997-03-05 | 1998-03-03 | Compuesto de sal de sodio de (acido (e) 4,6-dicloro-3-(2-oxo-1- fenilpirrolidin-3-ilideno-metil)-1h-indol-2-carboxilico en su forma hidratada,proceso para su preparacion, composicion farmaceutica que lo contiene y metodo de tratamiento utilizando dicho compuesto |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP0966463A1 (es) |
| JP (1) | JP2001513796A (es) |
| KR (1) | KR20000075907A (es) |
| CN (1) | CN1249750A (es) |
| AP (1) | AP9901637A0 (es) |
| AR (1) | AR011178A1 (es) |
| AU (1) | AU6825198A (es) |
| BG (1) | BG103779A (es) |
| BR (1) | BR9808305A (es) |
| CA (1) | CA2282851A1 (es) |
| CO (1) | CO4940415A1 (es) |
| EA (1) | EA199900710A1 (es) |
| EE (1) | EE9900387A (es) |
| GB (1) | GB9704498D0 (es) |
| HR (1) | HRP980114A2 (es) |
| HU (1) | HUP0002109A2 (es) |
| ID (1) | ID24207A (es) |
| IL (1) | IL131489A0 (es) |
| IS (1) | IS5166A (es) |
| NO (1) | NO994303L (es) |
| NZ (1) | NZ337315A (es) |
| OA (1) | OA11154A (es) |
| PE (1) | PE51399A1 (es) |
| PL (1) | PL335652A1 (es) |
| SK (1) | SK119699A3 (es) |
| TR (1) | TR199902117T2 (es) |
| WO (1) | WO1998039327A1 (es) |
| YU (1) | YU43499A (es) |
| ZA (1) | ZA981791B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9704499D0 (en) * | 1997-03-05 | 1997-04-23 | Glaxo Wellcome Spa | Method of manufacture |
| GB9825988D0 (en) * | 1998-11-27 | 1999-01-20 | Pfizer Ltd | Indole derivatives |
| GB9915231D0 (en) | 1999-06-29 | 1999-09-01 | Pfizer Ltd | Pharmaceutical complex |
| US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| EP3638234A1 (en) | 2017-06-12 | 2020-04-22 | Glytech LLC. | Treatment of depression with nmda antagonists and d2/5ht2a or selective 5ht2a antagonists |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9321221D0 (en) * | 1993-10-14 | 1993-12-01 | Glaxo Spa | Heterocyclic compounds |
-
1997
- 1997-03-05 GB GBGB9704498.6A patent/GB9704498D0/en active Pending
-
1998
- 1998-03-03 AU AU68251/98A patent/AU6825198A/en not_active Abandoned
- 1998-03-03 AR ARP980100948A patent/AR011178A1/es unknown
- 1998-03-03 ID IDW990976A patent/ID24207A/id unknown
- 1998-03-03 JP JP53813598A patent/JP2001513796A/ja active Pending
- 1998-03-03 PE PE1998000149A patent/PE51399A1/es not_active Application Discontinuation
- 1998-03-03 HU HU0002109A patent/HUP0002109A2/hu unknown
- 1998-03-03 BR BR9808305-8A patent/BR9808305A/pt not_active Application Discontinuation
- 1998-03-03 PL PL98335652A patent/PL335652A1/xx unknown
- 1998-03-03 ZA ZA9801791A patent/ZA981791B/xx unknown
- 1998-03-03 EA EA199900710A patent/EA199900710A1/ru unknown
- 1998-03-03 EP EP98913613A patent/EP0966463A1/en not_active Withdrawn
- 1998-03-03 CO CO98011404A patent/CO4940415A1/es unknown
- 1998-03-03 TR TR1999/02117T patent/TR199902117T2/xx unknown
- 1998-03-03 YU YU43499A patent/YU43499A/sh unknown
- 1998-03-03 CN CN98803053A patent/CN1249750A/zh active Pending
- 1998-03-03 WO PCT/EP1998/001146 patent/WO1998039327A1/en not_active Application Discontinuation
- 1998-03-03 SK SK1196-99A patent/SK119699A3/sk unknown
- 1998-03-03 KR KR1019997007987A patent/KR20000075907A/ko not_active Application Discontinuation
- 1998-03-03 AP APAP/P/1999/001637A patent/AP9901637A0/en unknown
- 1998-03-03 NZ NZ337315A patent/NZ337315A/en unknown
- 1998-03-03 IL IL13148998A patent/IL131489A0/xx unknown
- 1998-03-03 CA CA002282851A patent/CA2282851A1/en not_active Abandoned
- 1998-03-03 EE EEP199900387A patent/EE9900387A/xx unknown
- 1998-03-04 HR HR9704498.6A patent/HRP980114A2/hr not_active Application Discontinuation
-
1999
- 1999-08-27 IS IS5166A patent/IS5166A/is unknown
- 1999-09-02 OA OA9900201A patent/OA11154A/fr unknown
- 1999-09-03 NO NO994303A patent/NO994303L/no not_active Application Discontinuation
- 1999-10-04 BG BG103779A patent/BG103779A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU6825198A (en) | 1998-09-22 |
| JP2001513796A (ja) | 2001-09-04 |
| BR9808305A (pt) | 2000-05-16 |
| PL335652A1 (en) | 2000-05-08 |
| EA199900710A1 (ru) | 2000-04-24 |
| WO1998039327A1 (en) | 1998-09-11 |
| HRP980114A2 (en) | 1998-12-31 |
| YU43499A (sh) | 2000-12-28 |
| EP0966463A1 (en) | 1999-12-29 |
| BG103779A (en) | 2000-06-30 |
| TR199902117T2 (xx) | 2000-03-21 |
| HUP0002109A2 (hu) | 2001-04-28 |
| CA2282851A1 (en) | 1998-09-11 |
| NO994303D0 (no) | 1999-09-03 |
| IS5166A (is) | 1999-08-27 |
| PE51399A1 (es) | 1999-06-07 |
| NZ337315A (en) | 2001-02-23 |
| IL131489A0 (en) | 2001-01-28 |
| ID24207A (id) | 2000-07-13 |
| SK119699A3 (en) | 2000-05-16 |
| ZA981791B (en) | 1999-09-03 |
| EE9900387A (et) | 2000-04-17 |
| CN1249750A (zh) | 2000-04-05 |
| AP9901637A0 (en) | 1999-09-30 |
| KR20000075907A (ko) | 2000-12-26 |
| OA11154A (en) | 2003-04-16 |
| NO994303L (no) | 1999-11-03 |
| CO4940415A1 (es) | 2000-07-24 |
| GB9704498D0 (en) | 1997-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT915898E (pt) | Forma i cristalina de claritromicina | |
| BR9714082A (pt) | Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto. | |
| BR9911482A (pt) | Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto | |
| ATE201597T1 (de) | Verabreichung von riluzol zur behandlung von neuro-aids | |
| ES2170813T3 (es) | Acidos 2,2-dicloroalcanocarboxilicos, proceso para su preparacion, medicamentos que los contienen y su uso para tratar la resistencia a la insulina. | |
| BR0212787A (pt) | Composto ou sal farmaceuticamente aceitável do mesmo, métodos de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto ou sal, e, composição farmacêutica | |
| AR019496A1 (es) | Azalidas de 13 miembros, composiciones farmaceuticas, uso en la preparacion de medicamentos y preparacion de los mismos | |
| ES2134801T3 (es) | Monohidrato de hidrocloruro de tiagabina cristalina, su preparacion y su uso. | |
| AR018162A1 (es) | Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica | |
| BR9507381A (pt) | Composto uso de um composto processo para o tratamento de um manifero composição famacèutica e processo para a preparação de compostos | |
| BR0011339A (pt) | Composto, uso, e processo para preparar o mesmo, composição farmacêutica, e, método para tratar uma condição de doença mediada por metaloproteinase | |
| AR011178A1 (es) | Compuesto de sal de sodio de (acido (e) 4,6-dicloro-3-(2-oxo-1- fenilpirrolidin-3-ilideno-metil)-1h-indol-2-carboxilico en su forma hidratada,proceso para su preparacion, composicion farmaceutica que lo contiene y metodo de tratamiento utilizando dicho compuesto | |
| ES2187534T3 (es) | Procedimiento para la preparacion de n-metil-3-(metil-4-piperi dinil)-14-indol-5-etanosulfonamida. | |
| MX9400165A (es) | Derivados de ter-butilergolina, proceso para su produccion y composiciones farmaceuticas que los contienen. | |
| BR9611276A (pt) | Composto formulação farmacêutica processo para tratamento ou profilaxia de doenças ou condições de seres humanos e uso de um composto | |
| AR002191A1 (es) | Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion, procedimiento para su preparacion | |
| AR031126A1 (es) | Acidos amino(oxo)aceticos inhibidores de la proteina tirosina fosfatasa | |
| AR008236A1 (es) | Forma cristalina anhidra del clorhidrato de acido r(-)-n-(4,4-di(3- metiltien-2-il)but-3-enil)-nipecotico, una composicion farmaceutica y el uso de dicha sal cristalina para la preparacion de una composicion farmaceutica | |
| ES2065855B1 (es) | Procedimiento para la preparacion de nuevos derivados desoxiazafosfolipidicos con accion inhibidora de la fosfolipasa a2, nuevos derivados desoxiazafosfolipidicos obtenidos y utilizacion de los mismos. | |
| ES2170377T3 (es) | Composicion que contiene quitosana. | |
| BR0317425A (pt) | Sal de rabeprazol, composição farmacêutica contendo o mesmo e processo para sua preparação | |
| BR0317445A (pt) | Composto, composição farmacêutica, método para o tratamento de doenças, e, uso de um composto | |
| ZA824649B (en) | New optically active dipeptides, process for their preparation and pharmaceutical products containing these compounds | |
| ES2158089T3 (es) | Uso de derivados de fosforo de alcaloides para el tratamiento de endocrinopatias. | |
| ES2062940A1 (es) | Agente gastrocinetico, proceso para su preparacion y composiciones farmaceuticas que lo contengan. |